Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2023; 29(29): 4481-4498
Published online Aug 7, 2023. doi: 10.3748/wjg.v29.i29.4481
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan, Yan Zhang
Liang-Fang Wang, Ping-Run Chen, Shi-Hao Duan, Yan Zhang, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Liang-Fang Wang, Ping-Run Chen, Si-Ke He, Shi-Hao Duan, Yan Zhang, West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Wang LF and Zhang Y contributed to the study conception and design; Wang LF and Chen PR reviewed the literature and wrote the manuscript; He SK and Duan SH critically reviewed the manuscript; and all authors approved the final version of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Zhang, MD, PhD, Chief Physician, Doctor, Professor, Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, No. 37 Guoxue Street, Chengdu 610041, Sichuan Province, China. hxzyan@163.com
Received: March 23, 2023
Peer-review started: March 23, 2023
First decision: June 17, 2023
Revised: June 28, 2023
Accepted: July 17, 2023
Article in press: July 17, 2023
Published online: August 7, 2023
Processing time: 131 Days and 20.3 Hours
Core Tip

Core Tip: Tumor necrosis factor-α (TNF-α) antagonists play an essential role in the management of inflammatory bowel disease (IBD). However, a significant number of patients experience primary or secondary nonresponse to these drugs. Here, we summarize relevant predictors of anti-TNF nonresponse in IBD and discuss the next steps for treating patients with primary or secondary nonresponse to anti-TNF agents.